Details
Femara Indications
· Adjuvant therapy for hormone-positive invasive breast cancer in the early stages in postmenopausal women.
· Extended adjuvant therapy for early-stage invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years.
· First-line therapy for hormone-dependent advanced breast cancer in postmenopausal women.
· Treatment of common forms of breast cancer in postmenopausal women (natural or artificially induced) after recurrence or progression of the disease who have received prior antiestrogen therapy.
· Neoadjuvant therapy in postmenopausal women with hormone-positive, HER-2-negative breast cancer who do not respond to chemotherapy and do not require immediate surgery.
The effectiveness of the drug for patients with hormone-negative breast cancer has not been proven.
Contradictions
· Hypersensitivity to the active substance or to any other component of the drug.
· Endocrine status characteristic of the premenopausal period.
· Pregnancy, breastfeeding.
· Reproductive age of the patient.
Dosage & Administration
Adults, including elderly patients. The recommended dose of Femara is 2.5 mg once daily. In adjuvant and advanced adjuvant therapy, treatment with Femara® should be continued for 5 years or until the disease relapses. In patients with metastases, Femara® therapy should be continued until signs of disease progression become apparent. Adjuvant therapy should also be considered in the setting of adjuvant therapy (letrozole for 2 years, followed by switching to tamoxifen for 3 years).
In neoadjuvant treatment, Femara® therapy should be continued for 4 to 8 months to achieve optimal tumor reduction. If the response to treatment is insufficient, Femara® therapy should be discontinued and scheduled surgery instituted and / or further treatment options discussed with the patient.
No dose adjustment is required for elderly patients.
